Details for New Drug Application (NDA): 214971
NDA 214971 describes SODIUM NITROPRUSSIDE, which is a drug marketed by Abraxis Pharm, Amneal, Amphastar Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Be Pharms, Caplin, Chartwell Rx, Cipla, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Hainan Poly, Micro Labs, Mylan Labs Ltd, Nexus, Pharmobedient, Sagent Pharms Inc, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, and Xiromed, and is included in twenty-three NDAs. It is available from twelve suppliers. Additional details are available on the SODIUM NITROPRUSSIDE profile page.
The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
Summary for 214971
| Tradename: | SODIUM NITROPRUSSIDE |
| Applicant: | Be Pharms |
| Ingredient: | sodium nitroprusside |
| Patents: | 0 |
Pharmacology for NDA: 214971
| Physiological Effect | Vasodilation |
Suppliers and Packaging for NDA: 214971
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 214971 | ANDA | BE Pharmaceuticals Inc. | 71839-120 | 71839-120-01 | 1 VIAL in 1 CARTON (71839-120-01) / 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 25MG/ML | ||||
| Approval Date: | Jul 12, 2021 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
